Literature DB >> 32396621

Two distinct prognostic groups in advanced-stage Hodgkin lymphoma revealed by the presence and site of bulky disease.

Shunan Qi1,2, Sarah Milgrom3,4, Bouthaina Dabaja3, Richard Tsang5, Mario Levis6, Umberto Ricardi6, Rebecca Lopez-Alonso7, Eldad J Dann8, Andrea Ng9, Joachim Yahalom1.   

Abstract

Controversy exists regarding the definition and prognostic significance of bulk in advanced-stage (stage III/IV) Hodgkin lymphoma (ASHL), and bulk location (mediastinum vs other sites) further complicated the setting. This retrospective, multi-institutional study comprised 814 ASHL patients between 2000 and 2010 and aimed to evaluate the significance of bulk in ASHL. End points of interest included progression-free survival (PFS) and overall survival (OS). Covariates included maximum diameter and the site of bulky disease. SmoothHR and Kaplan-Meier analyses were used to assess for an association of PFS and OS with covariates. In the exploratory cohort (n = 683), maximum diameter had no association with PFS and a complex, U-shaped association with all-cause mortality on smoothHR analysis. Using 5 cm as a cutoff for bulk, Kaplan-Meier analyses confirmed the smoothHR results. The site of bulk was incorporated to divide patients into 2 groups. The mediastinal bulk (MB) type had more favorable characteristics than the nonbulky/non-MB (NB/NMB) type on age, histology, and bone marrow involvement (P < .001). The MB type was associated with better OS than the NB/NMB-type on univariable analysis (5-year OS, 92% vs 86%; HR, 0.53; 95% confidence interval, 0.34-0.84; P = .007). These findings persisted in the subgroup treated with chemotherapy alone and were confirmed in an independent validation cohort (n = 131). Our findings indicate that mediastinal bulk was associated with more favorable disease characteristics and improved OS in ASHL, and may be a surrogate of a more favorable biology.
© 2020 by The American Society of Hematology.

Entities:  

Year:  2020        PMID: 32396621      PMCID: PMC7218436          DOI: 10.1182/bloodadvances.2019001265

Source DB:  PubMed          Journal:  Blood Adv        ISSN: 2473-9529


  33 in total

1.  Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group.

Authors:  Sally F Barrington; N George Mikhaeel; Lale Kostakoglu; Michel Meignan; Martin Hutchings; Stefan P Müeller; Lawrence H Schwartz; Emanuele Zucca; Richard I Fisher; Judith Trotman; Otto S Hoekstra; Rodney J Hicks; Michael J O'Doherty; Roland Hustinx; Alberto Biggi; Bruce D Cheson
Journal:  J Clin Oncol       Date:  2014-09-20       Impact factor: 44.544

2.  Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification.

Authors:  Bruce D Cheson; Richard I Fisher; Sally F Barrington; Franco Cavalli; Lawrence H Schwartz; Emanuele Zucca; T Andrew Lister
Journal:  J Clin Oncol       Date:  2014-09-20       Impact factor: 44.544

Review 3.  The 2016 revision of the World Health Organization classification of lymphoid neoplasms.

Authors:  Steven H Swerdlow; Elias Campo; Stefano A Pileri; Nancy Lee Harris; Harald Stein; Reiner Siebert; Ranjana Advani; Michele Ghielmini; Gilles A Salles; Andrew D Zelenetz; Elaine S Jaffe
Journal:  Blood       Date:  2016-03-15       Impact factor: 22.113

4.  Consolidation radiotherapy in patients with advanced Hodgkin's lymphoma: survival data from the UKLG LY09 randomized controlled trial (ISRCTN97144519).

Authors:  Peter W M Johnson; Matthew R Sydes; Barry W Hancock; Michael Cullen; John A Radford; Sally P Stenning
Journal:  J Clin Oncol       Date:  2010-05-24       Impact factor: 44.544

5.  Eight cycles of escalated-dose BEACOPP compared with four cycles of escalated-dose BEACOPP followed by four cycles of baseline-dose BEACOPP with or without radiotherapy in patients with advanced-stage hodgkin's lymphoma: final analysis of the HD12 trial of the German Hodgkin Study Group.

Authors:  Peter Borchmann; Heinz Haverkamp; Volker Diehl; Thomas Cerny; Jana Markova; Anthony D Ho; Hans-Theodor Eich; Hans Konrad Mueller-Hermelink; Lothar Kanz; Richard Greil; Andreas Rank; Ursula Paulus; Lenka Smardova; Christoph Huber; Bernd Dörken; Christoph Nerl; Stefan W Krause; Rolf-Peter Mueller; Michael Fuchs; Andreas Engert
Journal:  J Clin Oncol       Date:  2011-10-11       Impact factor: 44.544

6.  Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD11 trial.

Authors:  Hans Theodor Eich; Volker Diehl; Helen Görgen; Thomas Pabst; Jana Markova; Jürgen Debus; Anthony Ho; Bernd Dörken; Andreas Rank; Anca-Ligia Grosu; Thomas Wiegel; Johann Hinrich Karstens; Richard Greil; Normann Willich; Heinz Schmidberger; Hartmut Döhner; Peter Borchmann; Hans-Konrad Müller-Hermelink; Rolf-Peter Müller; Andreas Engert
Journal:  J Clin Oncol       Date:  2010-08-16       Impact factor: 44.544

7.  Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10 years of follow-up of the GHSG HD9 study.

Authors:  Andreas Engert; Volker Diehl; Jeremy Franklin; Andreas Lohri; Bernd Dörken; Wolf-Dieter Ludwig; Peter Koch; Mathias Hänel; Michael Pfreundschuh; Martin Wilhelm; Lorenz Trümper; Walter-Erich Aulitzky; Martin Bentz; Mathias Rummel; Orhan Sezer; Hans-Konrad Müller-Hermelink; Dirk Hasenclever; Markus Löffler
Journal:  J Clin Oncol       Date:  2009-08-24       Impact factor: 44.544

8.  A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease.

Authors:  D Hasenclever; V Diehl
Journal:  N Engl J Med       Date:  1998-11-19       Impact factor: 91.245

9.  Dose-adjusted EPOCH-rituximab therapy in primary mediastinal B-cell lymphoma.

Authors:  Kieron Dunleavy; Stefania Pittaluga; Lauren S Maeda; Ranjana Advani; Clara C Chen; Julie Hessler; Seth M Steinberg; Cliona Grant; George Wright; Gaurav Varma; Louis M Staudt; Elaine S Jaffe; Wyndham H Wilson
Journal:  N Engl J Med       Date:  2013-04-11       Impact factor: 91.245

10.  smoothHR: an R package for pointwise nonparametric estimation of hazard ratio curves of continuous predictors.

Authors:  Luís Meira-Machado; Carmen Cadarso-Suárez; Francisco Gude; Artur Araújo
Journal:  Comput Math Methods Med       Date:  2013-12-12       Impact factor: 2.238

View more
  1 in total

1.  The neutrophil to lymphocyte ratio (NLR) and the presence of large nodal mass are independent predictors of early response: A subanalysis of the prospective phase II PET-2-adapted HD0607 trial.

Authors:  Alessandra Romano; Chiara Pavoni; Francesco Di Raimondo; Corrado Tarella; Simonetta Viviani; Andrea Rossi; Caterina Patti; Marco Picardi; Maria Cantonetti; Giorgio La Nasa; Livio Trentin; Silvia Bolis; Valerio Zoli; Paolo Gavarotti; Paolo Corradini; Michele Cimminiello; Corrado Schiavotto; Guido Parvis; Roberta Zanotti; Guido Gini; Andrés J M Ferreri; Piera Viero; Stephane Chauvie; Alberto Biggi; Alessandro Massimo Gianni; Andrea Gallamini; Alessandro Rambaldi
Journal:  Cancer Med       Date:  2020-11-06       Impact factor: 4.452

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.